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TITLE 
ABSTRACT 
A Randomised Control Trial comparing the effects of Honey versus Sucrose as analgesia during 
routine venepuncture in newborn 
 
OBJECTIVE 
To determine the effectiveness and short term side effects of honey as analgesia in comparison to 
sucrose during routine venepuncture in newborn. 
 
METHODS 
A total of 78 term neonates were recruited from the Neonatal Intensive Care Unit and Special 
Care Nursery of Hospital Universiti Sains Malaysia. These neonates were randomized into two 
equal sized group receiving either 2 ml of oral 24% sucrose or 2 ml of Tualang honey  2 minutes 
prior to venepuncture. The whole procedure was videotaped. The degree of pain score using 
PIPP and duration of crying time were determined twice by two independent observer. The 
Mann Whitney U test was used to compare the pain scores and duration of cry between the study 
groups while the Wilcoxon sign rank test was used to compare differences within each group. 
 
 
ix 
 
RESULTS 
The result showed no significant differences in the demographic characteristics of the neonates. 
The median values of PIPP at 30 seconds and 150 seconds were comparable (p value = 0.871) 
between both groups (median PIPP sucrose = 5, 3 median PIPP for honey = 5, 2 respectively). 
The median PIPP score within each group was significantly higher (p value = 0.00) at 30 seconds 
(median =5) compared to at 150 seconds (median = 2.5). The duration of audible cry after 
venepuncture was not statistically significant (p=0.803) in neonates receiving honey (median= 
5.5 seconds) compared to neonates receiving 24% sucrose (median = 4 seconds). No neonates 
developed hyperglycemia, diarrhea or glycosuria in this study. 
. 
 
CONCLUSION 
In conclusion, this study strongly suggests that Tualang honey is not more effective than sucrose 
for procedure related analgesia in neonates. The absence of adverse effects following the 
administration of small amounts of honey to neonates may facilitate further studies using 
different doses or different types of honey.  
 
 
 
 
x 
 
 
TAJUK 
ABSTRAK 
Kajian perbandingan secara rawak buta  mengenai madu dan sukrosa sebagai ubat penahan sakit 
semasa pengambilan darah di kalangan bayi baru lahir. 
 
OBJEKTIF 
Untuk menilai keberkesanan dan kesan sampingan madu sebagai ubat penahan sakit dan 
membandingkannya dengan sukrosa ketika pengambilan darah di kalangan bayi baru lahir. 
 
TATACARA 
Sejumlah tujuh puluh lapan bayi yang dilahirkan cukup bulan telah dipilih dari wad intensif dan 
wad penjagaan khas bayi Hospital Universiti Sains Malaysia untuk kajian pengawalan secara 
rawak buta. Tiga puluh sembilan bayi telah diberi 2 ml air sukrosa 24% manakala tiga puluh 
sembilan bayi diberi 2 ml madu tualang, 2 minit sebelum pengambilan darah. Reaksi bayi 
dirakamkan didalam pita video sepanjang prosedur dijalankan. Skor tahap kesakitan bayi telah 
dinilai menggunakan Premature Infant Pain Profile(PIPP) dan julat masa tangisan bayi telah 
ditentukan dengan melihat pita rakaman prosedur oleh dua orang penyelidik secara rawak. 
 
xi 
 
KEPUTUSAN 
Keputusan dari kajian ini menunjukkan tiada perbezaan bererti bagi ciri-ciri demografik bayi di 
antara dua kumpulan tersebut. Nilai median PIPP pada 30 saat adalah sama di antara kumpulan 
iaitu 5  manakala nilai median PIPP pada 150 saat adalah 3 untuk kumpulan sukrosa dan 2 untuk 
kumpulan madu (p= 0.871 ). Perbandingan median PIPP di dalam kumpulan menunjukkan nilai 
median pada 30 saat adalah lebih tinggi berbanding dengan median pada 150 saat (p=0.00). Nilai 
median julat masa tangisan selepas venepunktur adalah sama (p=0.803) di antara bayi yang 
menerima madu (median 5.5 saat) dibandingkan bayi yang menerima 24% sukrosa ( median = 4 
saat). Tiada bayi di dalam kajian ini yang menunjukkan kesan sampingan seperti kandungan gula 
tinggi dalam darah, cirit birit atau kehadiran gula didalam air kencing . 
 
KESIMPULAN  
Kajian ini menunjukkan bahawa madu Tualang adalah tidak lebih berkesan daripada sukrosa 
sebagai ubat penahan sakit untuk prosedur di kalangan bayi. Ketiadaan kesan sampingan akibat 
penggunaan madu ini boleh membantu penyelidikan seterusnya menggunakan dos dan jenis 
madu yang berlainan.  
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1. INTRODUCTION 
 
Pain, which is the fifth vital sign, is defined as an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, according to the International Association for 
the Study of Pain (IASP) (McCaffery M 1999). Newborn infants are subjected to procedural pain 
like venepuncture and heel prick as part of routine medical procedure. The exposure to these 
noxious stimuli will engender the stress response which has specific negative physiological 
effects (Henry 2004). Basically, untreated procedural pain can lead to adverse effect such as 
hyperalgesia on subsequent procedure. 
 
In realizing the importance of analgesia in the newborn, various methods have been employed 
for amelioration of pain during such procedure. To date, there are various modes of analgesia 
which can be categorized into non pharmacological and pharmacological methods. The use of 
local anesthetics such as EMLAS is an example of a pharmacological agent used in treating pain. 
Other interventions like non nutritive sucking with pacifier, breastfeeding, rocking and handling 
the newborn during venepuncture has been shown to decrease the pain response in the neonates 
(Henry 2004). 
 
According to a recent Cochrane Review (Yamada 2010), oral sweet solution such as sucrose can 
significantly confer analgesic effects during minor procedure like venepuncture. Sucrose at a 
concentration more than 24% has been shown to be a safe and effective method of analgesia 
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(Yamada 2010). It is postulated that this effect takes place via the activation of the endogenous 
opiod system through taste (Blass 1999). 
 
However, little is known regarding the analgesic effect of another naturally sweet substance-
honey. This study aims to establish the analgesic effect of honey and to compare its effectiveness 
with sucrose as well as to delineate it’s safety as an analgesia. Honey forms part of traditional 
medicine in many cultures, although it is widely used as a sweetener (Gomez-Carava 2006). It is 
composed of at least 181 components and is basically a solution supersaturated in sugars, namely 
fructose (38%) and glucose (31%). Its moisture content is about 17.7% with a total acidity of 
0.08% and ashes content 0.18% (Nagai 2002). 
 
In addition, there is a great variety of minor components, including phenolic acids and 
flavonoids, the enzyme glucose oxidase and catalase, ascorbic acid, carotenoids, organic acid, 
amino acid, protein and alpha tocopherol (Ferreres 1993). The actual composition of honey 
varies depending on many factors such as the pollen source, climate, environmental conditions 
and the processing it undergoes (Gheldof 2002). 
 
Most of the functional and biological properties of honey are conferred by the phenolic 
compounds in the form of flavonoids as mentioned before. These properties include anti-oxidant, 
anti inflammatory, anti bacterial, anti viral, anti ulcerous and the capacity for the inhibition of 
enzymatic browning in fruits and vegetables (Viuda 2008). These biological properties of honey 
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especially the anti inflammatory and thus analgesic effects of honey will be established in this 
study using a locally derived Malaysian honey- the Tualang honey. This honey will be supplied 
by the Pharmacology Department, HUSM after undergoing a process of Gamma irradiation. This 
is done to eliminate all potential microorganisms including spore forming bacteria like 
Clostridium botulinum and yeast. To ensure the safety of honey which will be used in the 
neonatal period, stringent methods of precaution will be taken where samples of honey will be 
cultured prior and after undergoing radiation treatment. 
 
. 
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2.  LITERATURE REVIEW 
2.1 NEUROBIOLOGY AND NEUROANATOMY OF PAIN IN NEONATES 
Neonatal analgesia is a recent issue: newborns were supposed to feel no pain until the late 
1980’s, but from that date many studies were performed to verify the extent of neonatal pain 
perception, ways to measure and overcome it. Neonatal care is advancing to levels where more 
neonates are being offered more invasive intervention and prolonged hospital stay. Needless to 
say, majority of these interventions are painful and a specific methods of analgesia need to be 
given and specific guidelines implemented to address this issue of neonatal pain.  
 
During fetal development in utero, sensory fibers are abundant by 20 weeks; a functional spinal 
reflex is present by 19 weeks; connections to the thalamus by 20 weeks and connections to 
subplate neurons are present by 17 weeks with intensive differentiation by 25 weeks. These cells 
are important developmentally, but decline as a result of natural apoptosis (Lowery et al 2007). 
Neurobiological studies showed that from 30 weeks in utero, the anatomical and physiological 
system for pain transmission is already developed, with the establishment of mature 
thalamocortical projections from periphery to cortex (Goncalves 2010). 
 
Pain requires both nociception and emotional reaction or interpretation. It is normally triggered 
by messages transmitted from specialized receptors (nociceptors) in the body to integrative 
centers in the spinal cord and brainstem and on to the brain, where it undergoes higher sensory 
and cognitive analysis, allowing the body to respond appropriately to the stimuli (Slater 2008). 
7 
 
Nociception causes physiologic stress with activation of the hypothalamus-pituitary-adrenal axis, 
autonomic nervous system and hemodynamic changes. The changes induced by strong 
nociceptive stimulation in newborn have important postnatal consequences since they affect 
future reactions to noxious stimuli (Taddio 2009). Central sensitization and immaturity of the 
pain inhibitory system are the main neurobiological explanation for increased pain in neonates 
(Goncalves 2010). 
 
2.2 PHYSIOLOGY OF NOCICEPTION (PAIN SENSATION) 
Nociception is related to the mechanisms elicited by stimuli threatening the integrity of the 
individual. At the peripheral level, unmyelinated C fibres (C polymodal nociceptores) or fine 
myelinated A delta fibres are excited by noxious stimulation, directly or indirectly by 
inflammatory processes. Nociceptive afferent fibres terminate in the superficial laminae of the 
dorsal horn of the spinal cord where informations are integrated and controlled. These first 
synapses are modulated by excitatory amino acids (glutamate and aspartate) and many peptides 
(substance P, CGRP, CCK, endogenous opiods). Majority of the ascending pathways involved in 
nociception are located in the ventrolateral contralateral quadrant of the cord (spinoreticular and 
spinothalamic tracts). Many supraspinal sites are activated following nociceptive stimuli, with 
relays in the reticular formation of the brain stem (including the subnucleus reticularis dorsalis), 
the ponto-mesencephalic regions (periaqueductal gray matter and parabrachial area) and thalamic 
sites. Amygdala and hypothamic targets could be involved in motivational reactions and 
neuroendocrine adaptations to a noxious event. The cingular, insular and somatosensory cortices 
also receive nociceptive informations. Nociceptive signals are modulated at all levels of their 
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transmission; the more extensively studied controls are located at the spinal level (Guirimand 
1996). Spinal signals can also be inhibited following activation of bulbospinal descending 
inhibitor pathways and release of serotonin, norepinephrine and indirectly, endogenous opiods. 
Inhibitory controls triggered by noxious stimuli could facilitate the extraction of the nociceptive 
tone of informations having priority over other stimuli (Guirimand 1996). 
 
2.3 NEUROCHEMICAL SYSTEMS ASSOCIATED WITH PAIN PERCEPTION 
2.3.1 ENDOGENOUS OPIOD SYSTEM 
A research has demonstrated that at 15 weeks of gestation, functionally mature endorphinergic  
cells have been observed in the human fetal pituitary gland (Li et al 1979). By twenty weeks of 
gestation, in vitro stimulation of these fetal pituitary cells by corticotrophin-releasing factor may 
result in secretion of the beta-endorphins (Gibbs et al 1982). Endogenous opiod are released in 
the human fetus at birth and in response to neonatal distress (Gautray et al 1977). A study by 
Wardlaw et al showed that umbilical cord plasma levels of beta-endorphins and beta-lipotropin 
from healthy full-term neonates delivered vaginally have been shown to be three to five times 
higher than plasma levels in the resting adults (Wardlaw et al 1979). In addition to that, neonates 
delivered vaginally by breech presentation or vacuum extraction had further increases in beta-
endorphin levels, indicating beta-endorphin secretion in response to stress at birth (Puolakka et al 
1982). 
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The elevated values of endogenous opiod may have been caused by the stress inflicted by the 
illness, the pain associated with the clinical conditions mentioned above or the invasive 
procedure that the fetus had to undergo. Nonetheless, these high levels of beta endorphin are 
unlikely to decrease the analgesic requirements. This is because the cerebrospinal fluid levels of 
beta endorphin required to produce analgesia in human adults have been found to be 10 000 
times higher than the highest recorded level in neonates (Foley et al 1979). The high levels of 
beta endorphin and beta lipotropin in cord plasma reduces substantially by 24 hours after birth 
and reached adult levels by 5 days, whereas the levels in the cerebrospinal fluid fall to adult level 
by 24 hours (Facchinetti et al 1982). 
 
2.3.2 TACHYKININ SYSTEM 
The tachykinins are neurotransmitters which amplify pain perception from the periphery. Among 
the tachykinins, substance P has been widely investigated and shown to have a role in the 
transmission and control of pain impulses (Dickenson 1995). Neural elements containing 
substance P and its receptor appear in the dorsal root ganglia and dorsal horns of the spinal cord 
at 12 to 16 weeks of gestation (Charnay et al 1983). A high density of substance P fibres and 
cells have been observed in multiple areas of the fetal brain stem associated with the pathway for 
pain perception and control and the visceral reactions to pain (Del Fiacco 1984). 
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2.4 RATIONALE OF PROVIDING ANALGESIA TO NEONATES 
The ability to communicate about pain allows an individual to seek strategies to ease the pain, 
such as taking analgesics. Unfortunately, neonates do not possess this ability, thus making them 
vulnerable to prolonged suffering during their stay in the neonatal intensive care unit. The 
difficulty in accurate measurement of pain in the newborn is a major impediment in providing 
effective analgesia for neonates undergoing routine procedure like heel lance and venepuncture. 
Ignored and untreated pain in infants has been shown to have immediate and long-term effects as 
a result of structural and physiological changes within the nervous system. For example, the 
body responds to untreated pain by increased release of stress hormones, which may be 
associated with increased morbidity and mortality in the short term (Slater 2008). Furthermore, 
the associated changes caused by untreated pain may result in decrease oxygenation, 
hemodynamic instability and increase in intracranial pressure (Kyoung 2010). 
 
In a study by Bellieni et al, it is shown that even common routine procedure like heel prick can 
be potentially harmful for newborn if they provoke high level of pain (Bellieni et al 2009). In this 
study the generation of free radicals in the form of advanced oxidative protein product (AOPP) 
and total hydroperoxide (TH) was measured at the beginning and end of each heel prick and the 
level of pain was scored for every procedure. Significant increased in the free radicals was 
observed for those babies who showed highest pain intensity, thus stressing the need for any 
methods of analgesia to provide adequate pain relief during such procedure.   
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Further negative effects of untreated procedural pain was demonstrated by Taddio et al in her 
study on the effect of repeated painful procedure and development of hyperalgesia in the 
newborn. Hyperalgesia is defined as increase in response to a normally painful stimulus at a site 
distal from the site of injury. In this study, a total of 240 of both healthy infants and infants of 
diabetic mother were randomized into two groups and were subjected to venepuncture according 
to indications. It was found out that infants subjected to five or more venepuncture exhibit higher 
pain score and were prone to develop remote hyperalgesia (Taddio 2009). Finally, the long-term 
consequences of untreated pain may include altered pain perception, chronic pain syndromes, 
and somatic complaints such as sleep disturbances, feeding problems and inability to self-
regulate in response to internal and external stressors. It has been proposed that attention deficit 
disorders, learning disorders and behavioral problems in later childhood may be linked to 
repetitive pain in preterm infants (Slater 2008).  
 
2.5 METHODS OF PAIN ASSESSMENT FOR NEWBORN 
In realizing that pain in the newborn is often underestimated and at times left untreated, various 
different pain scales have been developed and validated specifically for this population. To date, 
several validated and reliable pain measures exist to assess acute pain in term and preterm 
neonates (Abu-Saad 1998). Both behavioral indicators of pain (e.g. facial expression, body 
movements, crying) and physiological indicators of pain (e.g. heart rate, respiratory rate, blood 
pressure, oxygen saturation, vagal tone, palmar sweating and plasma cortisol or cathecolamine 
levels) can be used to assess and manage pain in neonates. 
 
12 
 
It is interesting to note that facial expression is widely used to judge pain in neonates. However, 
little is known about the relationship between intensity of stimulus and nature of expression in 
term neonates. In a recent study by Schiavenato et al, little difference is noted on the eye and 
eyebrow between pain intensities. The mouth will open wider (vertically) in neonates 
experiencing higher pain stimulus. Qualitative differences in neonates facial expression to pain 
intensity may exist and the mouth may be an area in which to detect them. Nevertheless, further 
study regarding the generalizability of these findings is needed (Schiavenato 2011).  
 
Assessments that use multi-dimensional measures such as behavioral and physiological changes 
may result in more accurate assessment of neonatal pain (Stevens et al 1996). Composite 
measures of neonatal pain include the following: 1) the Neonatal Infant Pain Scale (NIPS) which 
assesses facial expression, cry, breathing patterns, movement of arms and legs and state of 
arousal (Lawrence et al 1993) 2) CRIES that assesses Crying, the Requirement for oxygen 
supplementation, Increases in heart rate and blood pressure, facial Expression and Sleeplessness ( 
Krechel & Bildner 1995)  3) the Premature Infant Pain Profile (PIPP) that includes behavioral( 
brow bulge, eye squeeze and nasolabial furrow), physiological (change in heart rate and change 
in oxygen saturation) and contextual (gestational age and behavioral state before painful 
stimulus)( Yamada 2010). Based on a review from 1996 to 2009, The PIPP continues to be a 
reliable and valid measure of acute pain in infants with numerous positive validation studies. 
There is substantial support for the use of PIPP as an effective measure in pain intervention 
studies in infants (Stevens et al 2010). 
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The latest pain scale to be developed is the COVERS scale, which incorporates 6 physiological 
and behavioral measures for scoring. In a study by Hand et al, pain assessment was done on 
newborns during heel prick using indicators from three previously established scales (CRIES, the 
Premature Infant Pain Profile and the Neonatal Infant Pain Scale) as well as the COVERS scale, 
depending upon gestational age. For  premature infant testing, similar results on pain assessment 
was obtained using the COVERS and PIPP scale while for full term infants, both the COVERS 
and NIPS scale resulted in similar pain assessment (Hand et al 2010). Another pain scale which 
is unidimensional in nature is the NFCS (Neonatal Facial Coding System). It is a valid and 
reliable coding system for quantifying facial actions associated with acute pain in infants 
(Grunau et al 1990).  
 
2.6 METHODS OF ANALGESIA FOR NEONATES 
2.6.1 PHARMACOLOGICAL METHODS OF ANALGESIA 
2.6.1.1 Opiod Analgesia  
Analgesia and sedation in Neonatal Intensive Care Unit (NICU) has been fraught with 
controversy because of concern over the safety of these drugs in the neonates, lack of adequate 
pharmacokinetic and pharmacodynamic data in this population, difficulty in pain assessment and 
lack of long term neurodevelopmental assessment of survivors for the pain experienced in the 
neonatal period (Hall 2009).  According to a study by Kapellou, preterm or ill neonates may 
undergo 1-21 heel pricks or venepunctures a day. Heel prick comprise 61% to 87% and 
venepunctures comprise 8% to 13% of invasive procedures performed on ill infants. The study 
14 
 
further stated that analgesics are rarely given specifically for blood sampling procedures despite 
the alarming statistics mentioned above (Kapellou 2011). 
 
MORPHINE 
Morphine is the most frequently used opioid analgesic in all ages, and is the most commonly 
used drug for analgesia in ventilated neonates (Hall 2007). Morphine has a slow onset of 
analgesia with a mean onset of action in 5 minutes and peak action at 15 minutes. It is 
metabolized in the liver into two active compounds, morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). The former is an opioid antagonist and the latter is a potent 
analgesic. Preterm infants mostly produce M3G, which explains why after 3–4 days of morphine 
therapy, the infant develops tolerance (Anand et al 2004). Side-effects of morphine include 
hypotension in neonates with pre-existing hypotension and gestational age less than 26 weeks, 
prolonged need for assisted ventilation and increased time to reach full feeds (Anand 2007). 
Others have suggested that morphine may have a specific effect on pulmonary mechanics, 
possibly due to some as yet undefined direct toxicity such as histamine release and/or 
bronchospasm (Levene 2005).  
 
FENTANYL 
Fentanyl is an opioid analgesic that is 50–100 times more potent than morphine. It is used 
frequently because of its ability to provide rapid analgesia. It may be used as a slow intravenous 
push every 2 to 4 hours or as a continuous infusion. Tolerance may develop and withdrawal 
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symptoms may occur after 5 days or more of continuous infusion. In a blinded randomized 
controlled trial, a single dose of fentanyl given to ventilated preterm newborns significantly 
reduced pain behaviors and changes in heart rate. It also increases growth hormone levels 
(Guinsburg 1998). In another study, fentanyl provided the same pain relief as morphine but with 
fewer side effects (Saarenmaa 1999). Side-effects of fentanyl include bradycardia, chest wall 
rigidity and opioid tolerance after prolonged therapy (Anand 2006). 
 
2.6.1.2 Non Opiod Analgesia 
MIDAZOLAM 
The most commonly used benzodiazepine in the NICU is midazolam. When administered with 
morphine, it has been shown to provide better sedation than morphine alone in ventilated 
patients, without adverse effects. Intranasal midazolam has been shown to be effective for 
fundoscopic exams in older children, but this mode of delivery has not been tested in neonates. 
One recent review found no apparent clinical benefit of midazolam compared to opiates in 
mechanically ventilated neonates (Aranda 2005). In addition, midazolam was associated with 
worse short term adverse effects (death, severe intraventricular hemorrhage or periventricular 
leukomalacia) in the NOPAIN trial compared to morphine alone (Anand et al 1999). In 
summary, midazolam appears to provide sedative effects in mechanically ventilated neonates, 
but it should be used with caution because of reported adverse effects, particularly when used 
alone. 
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KETAMINE 
Ketamine is a dissociative anesthetic used for anesthesia, analgesia and sedation. It causes 
bronchodilation and mild increase in blood pressure and heart rate (Betremieux 1993). Cerebral 
blood flow is relatively unaffected with ketamine, making it an attractive choice for some 
unstable hypotensive neonates requiring procedures such as cannulation for ECMO. Animal 
studies have raised concern over the neurodegenerative effects of ketamine; however it has been  
shown that ketamine in clinically relevant doses is neuroprotective in the presence of 
inflammatory pain (Anand 1999). Nevertheless, extrapolating animal to human data is 
problematic at best and there has been no credible evidence that ketamine is detrimental to the 
developing human brain in the presence of pain. Clearly, more study is needed to determine the 
safety and efficacy of this anesthetic. 
 
2.6.1.3 Local Anaesthetics 
Topical anesthetics [eutectic mixture of local anesthetic (EMLA)] have demonstrated 
effectiveness for certain types of procedural pain such as venipuncture, lumbar puncture or 
immunizations in children (Henry 2004).  In order to obtain the maximum benefit of this drug, 
EMLA should be applied at least 60 minutes prior to the scheduled procedure. Unfortunately, 
Taddio and coworkers in their review on the use of EMLA found that it had little benefit when 
used for heel prick, because of increased skin thickness (Taddio et al 1998). 
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The possible complications surrounding the use of EMLA which limits its used in the neonatal 
period is regarding the potential for developing methemoglobinemia and transient skin rashes 
(Henry 2004). This is based on the postulation that there is decreased level of methemoglobin 
reductase in infants under three months and this concern is accentuated especially so for the 
premature infants (Essink et al 1999). 
 
2.6.2 NON-PHARMACOLOGICAL METHODS OF ANALGESIA 
To date, there are vast arrays of non pharmacological methods that can be employed as analgesia 
in the newborn infants. Apart from relatively free of side effects, they are easy to use, 
inexpensive and can be as effective if not superior to some of the pharmacological agents 
available (Walter-Nicolet et al 2010).  
 
2.6.2.1 ORAL SWEET SOLUTIONS 
The most common intervention studied in regards to ameliorating the pain of routine heel sticks, 
venipuncture and injections is the use of oral sweet solution shortly before the start of the 
procedure. The use of oral sucrose alone or in conjunction with other measures like carrying, 
simulated rocking or non-nutritive sucking decreases pain responses in both full term and 
preterm neonates. The exact mechanism, optimum concentration and method of administration 
will be mentioned under the headings of Sucrose as an analgesia. Apart from sucrose, oral 
dextrose and oral glucose have also been shown to confer the analgesic effect. In a study by 
Alen, oral glucose at varying concentration of 10 to 30% vs. placebo was given 2 minutes prior 
18 
 
to venepuncture. The pain assessment was done using the “Leuven Pain Scale”. It was found out 
that the group receiving 2ml of 30% glucose given orally 2 minutes prior to venepuncture 
showed the most effective pain reduction in the newborn (Alen 2010).  
 
2.6.2.2 NON- NUTRITIVE SUCKING 
Another intervention that appears to decrease the pain response in neonates is non nutritive 
sucking. Non nutritive sucking is analgesic when the infant sucks on a pacifier at a rate of at least 
30 sucks per minute (Blass 1999). Sucking is effective in an additive manner when used in 
conjunction with sucrose solution, glucose solution or dextrose solution (American Academy of 
Pediatrics 2000). 
 
2.6.2.3 BREASTFEEDING 
Breastfeeding is also suggested as a mechanism to provide an analgesic effect in newborns 
undergoing venipuncture and heel stick. Mothers holding and breastfeeding their infants during 
venepuncture and the use of 30% glucose with pacifier were effective interventions for reducing 
a painful response in comparison to water or clothed mothers holding their infants. This finding 
is further supported by Okan et al, who found out in his study that the involvement of breast 
feeding and skin to skin contact can significantly reduce both physiological and behavioral pain 
response (Okan et al 2010). 
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2.6.2.4 ROCKING AND HOLDING 
Johnston and coworkers studied simulated rocking and holding with and without the use of 
sucrose in relation to decreasing pain during heel stick. The use of sucrose 24% alone and 
sucrose 24% with simulated rocking significantly decreased Neonatal Facial Coding System 
scores in comparison to rocking alone and water (Grunau 1987). However, there were no 
significant difference between sucrose and sucrose and rocking. In contrast, holding and sucrose 
24% were more effective than sucrose alone or holding alone in a study of healthy neonates 
undergoing heel lance (Johnston et al 1997). Alternatively, swaddling combined with positioning 
neonates upright during routine heel lance offers a nonpharmacological method of neonatal pain 
reduction during this procedure (Morrow 2010). 
 
2.7 SUCROSE AS ANALGESIA 
From the recent Cochrane Review, sucrose, a naturally occurring sweetener, has been shown to 
confer analgesic effects for newborn undergoing painful procedures like heel-lance, 
venepuncture, bladder catheterization, circumcision, ophthalmology examination and nasogastric 
tube insertion (Yamada 2010). It is postulated that the mechanism of action of sucrose is 
mediated by both the endogenous opiod system through taste and the non opiod system. Their 
underlying mechanisms of action may differ, however, they may act synergistically in conferring 
analgesia. Nevertheless, the exact mechanism of how sucrose activates the endogenous opiod 
system remains to be elucidated. 
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The greatest analgesic effect occurs when sucrose is administered approximately two minutes 
before the painful stimulus. This interval is thought to coincide with the release of endogenous 
opiod (Blass 1994). This is supported by the presence of opiod receptors on the tongue and 
animal studies demonstrating opiod-antagonist reversible analgesia during noxious stimulation 
(Shide 1989). 
 
The exact concentration by which sucrose is effective as analgesia has not been fully established. 
From the recent Cochrane review, small doses of 24% sucrose (0.01 to 0.02g) are efficacious in 
very low birth weight infants while larger doses (0.24 to 0.50g) reduce the proportion of crying 
time in term infants. A dose range of sucrose for reducing procedural pain in neonates was 
identified as 0.012 to 0.12g (0.05ml to 0.5 ml of sucrose 24% solution). It is recommended that 
the sucrose solution be administered two minutes prior to the painful procedure, as the peak 
effects appears to occur at two minutes and lasts approximately four minutes. 
 
Taddio et al, in his recent study has demonstrated the effectiveness and superiority of sucrose as 
analgesia when he compared this solution with another pharmacological agent, topical lidocaine 
during venepuncture in newborn (Taddio et al 2011). In this double blinded trial, 330 healthy 
term newborns were randomized into 3 groups: first group – received 1 g of topical liposomal 
lidocaine, second group – received 2 ml 24% sucrose 2 minutes prior to venepuncture, third 
group- received a combination of topical lidocaine and 24% sucrose. All infants were assessed 
using the facial grimacing score. The study concluded that 24% sucrose was more effective that 
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liposomal lidocaine for reducing pain during venepuncture in newborns. The addition of 
liposomal lidocaine to sucrose did not confer any additional benefit compared to sucrose alone.  
 
The superiority of sucrose over other non pharmacological method of analgesia is further shown 
by Altun in his study comparing 12.5% sucrose, hindmilk and distilled water. Each newborn 
infant will be randomized into three groups and will receive 1ml of the test solution before, 
during and after the heel prick procedure. Assessment of pain was done using the Neonatal 
Facial Coding System (NFCS) and it was found out that sucrose is more superior than hindmilk 
in conferring analgesic effect in  the newborn (Altun et al 2010). 
 
2.8 HONEY AND ITS BIOLOGICAL PROPERTIES 
Honey, a golden yellow viscous fluid containing sugars, results primarily from the 
transformation and concentration of nectars from flowers by two processes: interaction with the 
upper digestive tract secretion of the honey bee and concentration by water loss (>80%) in 
beehives (Biswa 2006). The content and composition of different types of honey vary with 
different floral sources as well as climatic and environmental condition (Gheldof 2002). As 
mentioned before, besides being supersaturated with sugars (mainly fructose and glucose), honey 
is also rich in carbohydrate, minerals, amino acids, protein and vitamins. Besides having these 
nutritional properties, honey is well known for its functional and biological properties which is 
conferred by the phenolic compound found in this solution (Viuda 2008). Chemically, phenolic 
compounds can be defined as substances that possess an aromatic ring bound with one or more 
hydrogenated substituents, including their functional derivatives (Marin 2001).  The main group 
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of phenolic compounds present in plants is derivatives of cinnamic acid, cumarins and flavonoids 
(Manthey 2001). In honey, most of the phenolic compounds are in the form of flavonoids, which 
concentration depends on various factors including plant species used by the bees, health of the 
plant, season and other environmental factors (Kucuk 2007). 
 
The functional properties of honey includes its capacity as an anti-oxidant, antibacterial, 
antiviral, anti-inflammatory, cardio-protective effects and prevention of enzymatic browning 
(Viuda 2008). These biological activity and therapeutic properties have been used for treatment 
of various diseases in many cultures dating back as far as during the era of Hippocrates, where it 
is used for the treatment of leg ulcers. In modern medicine, honey has been used successfully in 
the treatment of burns, graft donor sites, necrotizing fasciitis, neonatal post-op wound infection 
and skin ulcers. It has been observed both in clinical and experimental studies, that honey not 
only prevents infection around the wound, but also decreases inflammation and provides rapid 
tissue healing and epithelialization (Ozlugedik 2006). In addition, there are also well established 
studies using honey in the treatment of asthma, sore throat, cough and cold as well as prevention 
of radiation mucositis (Biswa 2006). 
 
Different mechanisms of action have been proposed to account for the biological properties of 
honey. Its high sugar content and low pH hinders microbial growth. In addition, honey is 
hygroscopic, resulting in shrinking of bacteria with the aid of its hyperosmolar properties. 
Furthermore, it can generate hydrogen peroxide, when diluted, through the activation of enzyme 
glucose oxidase which oxidizes glucose to gluconic acid and hydrogen peroxide (Farrokhi 2011). 
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The anti-inflammatory and immune modulatory effect can reduce oedema and the amount of 
tissue exudates by down regulating the inflammatory process. It also reduces pain by reducing 
both sensitization following inflammation-mediated prostaglandin synthesis and pressure on 
tissue resulting from oedema (Farrokhi 2011). In another study, Van Den Berg et al showed that 
buckwheat honey was most effective in reducing reactive oxygen species, thus acting as anti-
oxidant and this property is derived from its phenolic constituent (Van Den Berg  2008). 
 
Honey also possess moderate anti tumor and pronounced anti-metastatic effect in five different 
strains of rat and mouse tumor as demonstrated by a recent study by Grubel and Pashiniski. 
Compound like caffeic acid, phenethyl ester and flavonoid have been proven to have anti-
inhibitory effect on tumor cell proliferation and transformation by down regulation of many 
cellular enzymatic pathway (Ghandian 2011). Interestingly, in a study concerning medicinal 
properties of honey in Pakistan, it was demonstrated that the local honey showed anti-
nociceptive, anti bacterial and anti-platelet activity. This observation pointed to the potential of 
honey as an analgesia and anti inflammatory agent (Kamran 2007). 
 
This study was conducted in the hope to illustrate some of the analgesic and anti nociceptive 
properties of honey using a locally derived Tualang honey. This honey is a wild multi-floral 
honey found in the Rain Forest of Malaysia. The honey bee species is Apis Dorsata which built 
their hives high up in the Tualang tree (Koompassia excelsa) (Zaid S et al 2010). The Tualang 
honey was sterilized by Gamma irradiation at 25 kGy to eliminate all potential contamination 
especially botulinum spores. Studies have shown that radiation at 25 to 50 kGy do not affect the 
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quality of honey used (Yusof et al 2007). The honey was supplied by the Federal Agricultural 
Marketing Authority (FAMA), Malaysia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
